Plus   Neg

Regeneron Pharmaceuticals Q4 Income Rises

Regeneron Pharmaceuticals (REGN) released a profit for its fourth quarter that rose from last year.

The company said its bottom line advanced to $607 million, or $5.23 per share. This was up from $353 million, or $3.04 per share, in last year's fourth quarter.

Analysts had expected the company to earn $4.53 per share, according figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company said revenue for the quarter rose 28.5% to $1.58 billion. This was up from $1.23 billion last year.

Regeneron Pharmaceuticals earnings at a glance:

-Earnings (Q4): $607 Mln. vs. $353 Mln. last year.
-Earnings Growth (Y-o-Y): 72.0%
-EPS (Q4): $5.23 vs. $3.04 last year.
-EPS Growth (Y-o-Y): 72.0%
-Analysts Estimate: $4.53
-Revenue (Q4): $1.58 Bln vs. $1.23 Bln last year.
-Revenue Change (Y-o-Y): 28.5%

For comments and feedback contact: editorial@rttnews.com

Follow RTT